Donepezil

acetylcholinesterase (Cartwright blood group) ; Homo sapiens







333 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
301 10648652 Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease. 2000 Feb 2
302 10976649 Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. 2000 Sep 2
303 10984725 Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. 2000 Sep 1
304 10994012 Treatment of REM sleep behavior disorder with donepezil: a report of three cases. 2000 Sep 26 1
305 11068139 Donepezil dose-dependently inhibits acetylcholinesterase activity in various areas and in the presynaptic cholinergic and the postsynaptic cholinoceptive enzyme-positive structures in the human and rat brain. 2000 8
306 11078030 The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different. 2000 Oct 1
307 11198060 Adverse effects associated with the use of donepezil in general practice in England. 2000 1
308 11256231 Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. 2000 Oct 5
309 11343620 Management of cognition and function: new results from the clinical trials programme of Aricept(R) (donepezil HCl). 2000 Jul 1
310 22033801 A critical review of cholinesterase inhibitors as a treatment modality in Alzheimer's disease. 2000 Jun 2
311 9876215 Clinical profile of donepezil in the treatment of Alzheimer's disease. 1999 2
312 9924498 What's new in Alzheimer's disease treatment? Reasons for optimism about future pharmacologic options. 1999 Jan 1
313 10332937 Clinical benefits of a new piperidine-class AChE inhibitor. 1999 Apr 1
314 10363493 [Treatment of Alzheimer's disease: acetylcholinesterase inhibitors]. 1999 Apr 2
315 10447153 Defining meaningful change in Alzheimer's disease trials: the donepezil experience. 1999 Spring 1
316 10549687 Donepezil for psychotropic-induced memory loss. 1999 Oct 1
317 10622674 Assessing the societal impact of acetylcholinesterase inhibitor therapies. 1999 Nov 1
318 11249555 The pharmacology of donepezil: a new treatment of Alzheimer's disease. 1999 Nov 3
319 9475825 Donepezil use in Alzheimer disease. 1998 Jan 1
320 9771828 New cholinergic therapies: treatment tools for the psychiatrist. 1998 1
321 9839758 Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. 1998 Nov 6
322 9839759 Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. 1998 Nov 4
323 9853200 Perspectives in the management of Alzheimer's disease: clinical profile of donepezil. 1998 2
324 15616667 Alzheimer's disease therapy - an update. 1998 May 1
325 9062656 Abnormalities of acetylcholinesterase in Alzheimer's disease with special reference to effect of acetylcholinesterase inhibitor. 1997 Feb 1
326 9108896 Donepezil. 1997 Mar 2
327 9228650 Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia. 1997 May 2
328 9428950 Donepezil: an anticholinesterase inhibitor for Alzheimer's disease. 1997 Dec 15 3
329 9548205 Therapeutic advances: donepezil for the treatment of Alzheimer's disease. 1997 Aug 1
330 15989517 Donepezil (E2020): a new acetylcholinesterase inhibitor. Review of its pharmacology, pharmacokinetics, and utility in the treatment of Alzheimer's disease. 1997 Oct 4
331 8915035 The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. 1996 Nov-Dec 1
332 8535413 Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride (E2020). 1995 Aug 1
333 7738604 Prediction of the binding site of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine in acetylcholinesterase by docking studies with the SYSDOC program. 1994 Dec 3